Preoperative chemoradiation approaches to locally advanced non-small-cell lung cancer: one man’s pride, another man’s burden?

Open Access
Publisher Website
Google Scholar
Abstract
Has there been any major progress in the combined modality treatment for stage III locally advanced non-small-cell lung cancer (NSCLC) within the last 10 years? The answer is certainly yes, but currently we have to admit that the absolute gain for our patients has been relatively small, when looking from the broader perspective of the general patient population with NSCLC [1]. Differences in 5-year survival rates that have been achieved by complex bi- or tri-modality protocols have generally been observed in the range of between 3% and 7% improvement [2, 3]. Some therapists may be satisfied with these figures, others may not.

This publication has 15 references indexed in Scilit: